drugset / Trial / NCT03322293

Daylight Photodynamic Therapy for Actinic Keratosis

NCT03322293

Phase 1 Completed 24 enrolled University of California, San Francisco
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized, single-blind controlled trial with parallel group design to determine whether daylight photodynamic therapy (PDT) affords a reduction in treatment symptoms of pain, burning, and pruritus as measured by 1) symptom level during the treatment period and 2) pain at the end of treatment exposure.

Timeline

Start
2017-12-01
Primary completion
2018-12-01
Completion
2019-07-01

Drugs

EvaluationDrugModalityDoseRoute
Background Aminolevulinic Acid Diagnostic / imaging agent 20 % Topical

Indications